C WorldWide Group Holding A S Sells 75,000 Shares of Insmed, Inc. $INSM

C WorldWide Group Holding A S trimmed its stake in shares of Insmed, Inc. (NASDAQ:INSM) by 27.7% in the third quarter, according to the company in its most recent filing with the SEC. The firm owned 196,110 shares of the biopharmaceutical company’s stock after selling 75,000 shares during the quarter. Insmed comprises about 0.4% of C WorldWide Group Holding A S’s portfolio, making the stock its 28th biggest holding. C WorldWide Group Holding A S owned approximately 0.09% of Insmed worth $28,242,000 as of its most recent filing with the SEC.

Several other large investors also recently modified their holdings of the stock. Stone House Investment Management LLC bought a new stake in Insmed during the third quarter worth about $29,000. SBI Securities Co. Ltd. raised its position in shares of Insmed by 404.9% in the 3rd quarter. SBI Securities Co. Ltd. now owns 207 shares of the biopharmaceutical company’s stock valued at $30,000 after buying an additional 166 shares in the last quarter. MassMutual Private Wealth & Trust FSB lifted its holdings in shares of Insmed by 59.6% during the 3rd quarter. MassMutual Private Wealth & Trust FSB now owns 217 shares of the biopharmaceutical company’s stock worth $31,000 after acquiring an additional 81 shares during the period. FNY Investment Advisers LLC acquired a new stake in shares of Insmed during the 2nd quarter worth approximately $33,000. Finally, Whittier Trust Co. of Nevada Inc. boosted its position in shares of Insmed by 169.7% during the 3rd quarter. Whittier Trust Co. of Nevada Inc. now owns 240 shares of the biopharmaceutical company’s stock worth $38,000 after acquiring an additional 151 shares in the last quarter.

Wall Street Analysts Forecast Growth

Several research analysts have commented on the stock. Wolfe Research set a $167.00 price objective on shares of Insmed and gave the company an “outperform” rating in a research report on Thursday, December 18th. Jefferies Financial Group set a $269.00 price target on Insmed in a report on Wednesday, December 10th. Barclays initiated coverage on Insmed in a research note on Tuesday, January 27th. They issued an “overweight” rating and a $231.00 price objective on the stock. Royal Bank Of Canada boosted their target price on Insmed from $197.00 to $200.00 and gave the stock an “outperform” rating in a research note on Wednesday, January 21st. Finally, Wells Fargo & Company set a $195.00 target price on shares of Insmed in a research report on Thursday, December 18th. Three equities research analysts have rated the stock with a Strong Buy rating, twenty have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Buy” and an average price target of $206.04.

Insider Activity

In other news, Director Leo Lee sold 75,000 shares of the business’s stock in a transaction that occurred on Monday, November 17th. The shares were sold at an average price of $195.90, for a total value of $14,692,500.00. Following the transaction, the director owned 54,677 shares in the company, valued at approximately $10,711,224.30. The trade was a 57.84% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Orlov S. Nicole Schaeffer sold 87,290 shares of the stock in a transaction dated Friday, January 2nd. The stock was sold at an average price of $175.20, for a total value of $15,293,208.00. Following the sale, the insider owned 41,754 shares of the company’s stock, valued at approximately $7,315,300.80. The trade was a 67.64% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 274,857 shares of company stock worth $50,121,247 in the last 90 days. 3.00% of the stock is owned by company insiders.

Insmed Stock Down 3.0%

Shares of NASDAQ:INSM opened at $152.44 on Thursday. The firm has a market cap of $32.51 billion, a P/E ratio of -24.63 and a beta of 1.11. Insmed, Inc. has a 12-month low of $60.40 and a 12-month high of $212.75. The business has a fifty day simple moving average of $177.10 and a 200 day simple moving average of $159.66. The company has a quick ratio of 4.34, a current ratio of 4.63 and a debt-to-equity ratio of 0.59.

Insmed Company Profile

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.